This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered

A Leading Immunotherapy Biotech Company

Broad Late-Stage Clinical Platform of Antibody Cytokine Fusion Proteins, Albumin-Linked Chemo-Immunomodulators, Vaccine Vectors and Natural Killer cells NASDAQ:IBRX June 4, 2021 Exhibit 99.1

This presentation contains

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified

by the use of words such as "anticipates," "believes," "continues", "could", "estimates," "expects," "intends," "may," "plans,"

"potential", "predicts", "projects," "seeks," "should," "will," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our

clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performances or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are

based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such statements reflect the current views of ImmunityBio with respect to future events and are subject

to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) the ability of ImmunityBio to continue its planned

preclinical and clinical development of its development programs, and the timing and success of any such continued preclinical and clinical development and planned regulatory submissions, (ii) whether interim, initial, "top-line" and

preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data,

(iii) our ability to obtain additional financing to fund our operations and complete the development and commercialization of our various product candidates, (iv) uncertainty of the expected financial performance and successful integration of the

combined company following completion of the merger, including the possibility that the expected synergies and value creation from the merger will not be realized or will not be realized within the expected period, (v) inability to retain and

hire key personnel, and (vi) the unknown future impact of the COVID-19 pandemic delay on certain clinical trials or their milestones and/or ImmunityBio's operations or operating expenses. More details about these and other risks that may

impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on March 10, 2021 and in subsequent filings

made by ImmunityBio with the SEC, which are available on the SEC's website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not

undertake any duty to update any forward-looking statement or other information in this presentation, except to the extent required by law. Forward Looking Statements

ImmunityBio: A Leading Immunotherapy

Company 17 First in Human Immunotherapy Molecules and cells 40 Phase I / II / III Clinical Trials 1,800+ Patients Studied 25 Phase II / III Clinical Trials ~400,000 Square Feet of Manufacturing and R&D Facilities 5 Trillion Over 5 Trillion

Natural Killer Cells Manufactured to Date > Antibody Cytokine Fusion Proteins A Leading Immunotherapy Platform in Oncology & Infectious Diseases Chemo Immuno Modulators Vaccine Technologies Natural Killer Cells NASDAQ: IBRX 600+ Worldwide

Patents Extending to 2035 and Beyond 100+ Patients Dosed with Off-the-Shelf Natural Killer Cells NK Cells

Selected Clinical Pipeline Updates for

June 2021 Non-Muscle Invasive Bladder Cancer (NMIBC) Pancreatic Cancer Triple Negative Breast Cancer (TNBC) M-ceNK COVID-19 HIV Seminal Worldwide Patents

Selected Clinical Pipeline Updates for

June 2021 Non-Muscle Invasive Bladder Cancer (NMIBC) Pancreatic Cancer Triple Negative Breast Cancer (TNBC) M-ceNK COVID-19 HIV Seminal Worldwide Patents

BCG Unresponsive NMIBC CIS Registration

Trial FDA Breakthrough Designation BCG + Anktiva Administered Intravesically Intravesical BCG Anktiva (N-803) Bladder Catheter Medication FDA BREAKTHROUGH THERAPY DESIGNATION for BCG-Unresponsive NMIBC CIS N=80 FULLY ENROLLED

Pivotal Registration Data (QUILT-3.032)

in BCG-Unresponsive NMIBC CIS Primary Endpoint Met Secondary Endpoint Updated June 2021 CR at 12 months: 58% (95% CI: 42.9%, 71.1%) Probability of patients maintaining CR for 12 months Median Follow-Up Time: 16.1 Months Complete Response at 12

Months, Safety Population - Cohort A (CIS) CR at 12 Months: 58% (95% CI: 42.9%, 71.1%) NCT03022825 Primary Endpoint: CR at any time, with lower bound of 95% CI 20% To meet the primary endpoint, 24 out of 80 patients must have had a CR

at any time 56 out of 80 CR's have been reached CR rate at any time 70% (95% CI: 59%, 80%) CR rate confirmed by central review

Efficacy & Safety in Patients with

BCG-Unresponsive NMIBC CIS in QUILT-3.032 and Historical Comparison to Keytruda Efficacy Endpoints KEYNOTE-057 Keytruda QUILT-3.032 Anktiva + BCG CR Rate (95% CI) At any time or 3 months 41% (31%, 52%) 70% (59%, 80%) Duration of Response in

Responding Patients Median Duration of CR in Months (range) 16.2 (0.0+ - 26.8) 19.9 (0.0+ - 26.6) Cystectomy Free Rate % Cystectomy Free 63% 86% Immune-Mediated Adverse Event KEYNOTE-057 Keytruda QUILT-3.032 Anktiva + BCG Any

Immune-Mediated AE 21% 0 Grade 3-5 Immune-Mediated AEs 3% 0 Any Immune-Mediated SAE 5% 0 Discontinuation due to Immune-Mediated AEs 4% 0 Discontinuation due to Immune-Mediated SAEs 2% 0 Approved Jan 2020 A historical comparison. Not a head to head

Selected Clinical Pipeline Updates for

June 2021 Non-Muscle Invasive Bladder Cancer (NMIBC) Pancreatic Cancer Triple Negative Breast Cancer (TNBC) M-ceNK COVID-19 HIV Seminal Worldwide Patents

QUILT 88: 3rd Line or Greater

Metastatic Pancreatic Cancer PHASE 2 & spIND SECOND LINE OR GREATER COHORT C N=50 N=17 QUILT 88 Exploratory haNK + PD-L1 Inhibitor (Avelumab) Median Overall Survival (OS) = 8.0 months (95% CI: 5.0, 12.3) PD-L1 t-haNK Median Overall Survival (OS)

= 12.95 Months N = 42 (as of June 2021) Enrolled to Date 30 Alive to Date with Ongoing Follow-Up

QUILT 88: 3rd Line or Greater

Metastatic Pancreatic Cancer PHASE 2 & spIND SECOND LINE OR GREATER COHORT C N=50 N=17 QUILT 88 Exploratory

Phase 1/2 Trial of haNK + PD-L1 in

Combination with Chemo Immunomodulation in Advanced Metastatic Pancreatic Cancer NCT03329248 (Closed) QUILT 3.039, 3.060, 3.070, 3.080 NANT Cancer Vaccine Preliminary Data Lock Patients (2nd Line or Greater) Weeks of Follow Up or Until Death 1 2 3 4

5 6 7 8 9 10 11 12 2nd Line or Greater Metastatic Pancreatic Cancer Historical >2L Survival Rate (3 Months)1 haNK + PD-L1 Inhibitor (Avelumab) Median Overall Survival = 8.0 months (95% CI: 5.0, 12.3) NK Synergy in Pancreatic Cancer haNK + PD-L1

inhibitor (Avelumab) in Metastatic Pancreatic Cancer Median Overall Survival 8.0 Months, Doubling Historical Survival Rates 1. Accessed Jan 2020 - Taylor et al. Designing Clinical Trials in 3rd Line or Greater Pancreatic Cancer DOI:

10.1200/JCO.2019.37.4_suppl.226

Exploratory Trial of PD-L1 t-haNK in

Combination with Chemo Immunomodulation in Advanced Metastatic Pancreatic Cancer PD-L1 t-haNK in Metastatic Pancreatic Cancer Median Overall Survival (OS) is 394 Days (13 Months) Historical >2L Survival Rate (12 weeks) Weeks of Follow Up or Until

Death 1. Accessed Jan 2020 - Taylor et al. Designing Clinical Trials in 3rd Line or Greater Pancreatic Cancer DOI: 10.1200/JCO.2019.37.4_suppl.226 2nd Line or Greater Metastatic Pancreatic Cancer Patients (2nd Line or Greater) Ongoing Treatment

Median Overall Survival = 13 months

QUILT 88: 3rd Line or Greater

Metastatic Pancreatic Cancer PHASE 2 & spIND SECOND LINE OR GREATER COHORT C N=50 N=17 QUILT 88 Exploratory

Phase 2 Trial of PD-L1 t-haNK in

Combination with Chemo Immunomodulation in Advanced Metastatic Pancreatic Cancer NCT04390399 (QUILT-88) N=248 Actively Enrolling Historical >2L Survival Rate (12 weeks) Weeks of Follow Up or Until Death PD-L1 t-haNK + Chemo Immunomodulation in

Locally Advanced or Metastatic Pancreatic Cancer (QUILT-88) Last Updated June 2021 N = 42 to date 30 Alive to Date with Ongoing Follow-Up 1. Accessed Jan 2020 - Taylor et al. Designing Clinical Trials in 3rd Line or Greater Pancreatic Cancer DOI:

10.1200/JCO.2019.37.4_suppl.226

QUILT-88: NANT Pancreatic Cancer

Vaccine - Trial in Progress Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or

metastatic pancreatic cancer Abstract # 343497 BACKGROUND STUDY ENDPOINTS 2021 ImmunityBio ASCO Annual Meeting June 2021 REFERENCES Tara Seery1, Chaitali Nangia1, Leonard Sender2, Sandeep Reddy2, Patrick Soon-Shiong2 1Hoag Cancer Center,

Newport Beach, CA; 2, ImmunityBio Inc. Culver City, CA. CONTACT info@immunitybio.com 310-883-1300 Main 1. An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model Jaemin Lee, Tae

Heung Kang, Wonbeak Yoo, Hyunji Choi, Seongyea Jo, Kyungsu Kong, Sang-Rae Lee, Sun-Uk Kim, Ji-Su Kim, Duck Cho, Janghwan Kim, Jeong-Yoon

Kim, Eun-Soo Kwon and Seokho Kim DOI: 10.1158/2326-6066.CIR-18-0317 Published February 2019 2. Oh E, Min B, Li Y, Lian C, Hong J, Park GM, Yang B, Cho SY, Hwang YK, Yun CO. Cryopreserved Human Natural Killer

Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability (Running Title: Cryopreserved NK Cells Exhibit Antitumor Effect). Cancers (Basel). 2019 Jul 9;11(7):966. doi:

10.3390/cancers11070966. Pancreatic cancer will claim an estimated 47,050 lives in the USA in 2020, with an expected 5 year survival of 10%. Thus there is an urgent need for novel treatment options in this disease. We hypothesize that effective

response against pancreatic cancer requires a coordinated approach that orchestrates both the innate and adaptive immune system. We further hypothesize that by orchestrating the activation of the entire immune system, we could accomplish immunogenic

cell death with durable responses in this disease. We describe a novel combination immunotherapy protocol of low-dose chemoradiation, cytokine-induced NK and T cell activation via N-803 (Anktiva, IL-15 cytokine fusion protein), and off-the-shelf

PDL1-targeted high-affinity NK cell (PDL1 t-haNK) infusion. MAJOR INCLUSION CRITERIA MAJOR EXCLUSION CRITERIA STUDY DESIGN For Cohort A, subjects must have initially received, or are currently receiving, continuous treatment with gemcitabine plus

nab-paclitaxel for at least 16 weeks and have confirmed PR, CR, or SD prior to receiving first-line maintenance therapy on this study. Duration of actual initial treatment may be unlimited as long as no evidence of disease progression is noted by

the Investigator at the time of randomization. b. For Cohort B, subjects must have PD after receiving initial treatment with FOLFOX, FOLFIRINOX, or a gemcitabine- or paclitaxel-based therapy for pancreatic cancer. Subjects who discontinued prior

therapy due to toxicity, intolerance, or available therapy was clinically contraindicated are allowed. c. For Cohort C, subjects must have PD after receiving at least 2 lines of therapy for pancreatic cancer, including but not limited to

neoadjuvant, adjuvant, and/or metastatic settings. a. Absolute neutrophil count (ANC) < 1000 cells/mm3. b. Platelet count < 100,000 cells/mm3. Aldoxorubicin HCl, N-803 and PD-L1 t-haNK ImmunityBio, Inc. Clinical Trial Protocol: QUILT-88

Amendment 5 Confidential and Proprietary 10 c. Hemoglobin < 9 g/dL. d. Total bilirubin greater than two times the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome). e. Aspartate aminotransferase (AST [SGOT])

or alanine aminotransferase (ALT [SGPT]) > 2.5 ULN (> 5 ULN in subjects with liver metastases). f. Alkaline phosphatase (ALP) levels > 2.5 ULN (> 5 ULN in subjects with liver metastases, or > 10 ULN

in subjects with bone metastases). g. Serum creatinine > 2.0 mg/dL or 177 mol/L. h. Serum anion gap > 16 mEq/L or arterial blood with pH < 7.3. i. Albumin < 3.0. j. Ascites requiring paracentesis. COHORT A COHORT B COHORT C Days 1

and 15, every 4 weeks: Nab-paclitaxel Gemcitabine Days 1-5 and 15-19, every 4 weeks: Cyclophosphamide Days 1, 8, 15, and 22; for first cycle only: SBRT (not to exceed 8 Gy, exact dose to be determined by

the radiation oncologist) Day 8, every 4 weeks: Aldoxorubicin HCl N-803 (15 g/kg SC) Days 1, 8, and 15; every 4 weeks: PD-L1 t-haNK (~2 109 cells/dose IV) STUDY EXPERIMENTAL TREATMENT Primary Efficacy Endpoints:

PFS per RECIST V1.1 (Cohorts A and B). OS (Cohort C). Secondary Efficacy Endpoints: ORR, CR rate, DoR, and DCR (confirmed CR or PR, or SD for at least 2 months) by RECIST V1.1 OS (Cohorts A and B). PFS per

RECIST V1.1 (Cohort C). QoL by PROs. Safety Endpoints: Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events

(CTCAE) Version 5.0. Safety laboratory tests. Vital signs. Exploratory Endpoints: PFS, ORR, CR rate, DoR, and DCR per iRECIST. CA 19-9 levels and correlations with subject outcomes. Presenting at ASCO 2021

Selected Clinical Pipeline Updates

for June 2021 Non-Muscle Invasive Bladder Cancer (NMIBC) Pancreatic Cancer Triple Negative Breast Cancer (TNBC) M-ceNK COVID-19 HIV Patents

PD-L1 t-haNK Activity in Triple

Negative Breast Cancer

PD-L1 t-haNK Activity in Triple

Negative Breast Cancer ORR:67% Median PFS: 14.3 months Median OS: 20.2 months ImmunityBio Phase 1b / 2 TNBC Data (2nd Line or Greater) ORR was 33.3% (95% CI: 24.6, 43.1) Median response duration was 7.7 months (95% CI: 4.9, 10.8) April 2020 A

historical comparison. Not a head to head comparison Phase 1/2: Open-label, Phase 1/2 trial of sacituzumab plus Anktiva and PD-L1 t-haNK for the treatment of subjects with advanced triple-negative breast cancer after prior therapy. TNBC >2 Prior

Treatments for Metastatic Disease

TNBC Phase 1 / 2 Treatment Schema

ImmunityBio Investigational Agents In TNBC Clinical Trial PD-L1 t-haNK Anktiva (N-803) Cytokine Cytokine Fusion Antibody (IgG1) TNBC - Triple Negative Breast Cancer Phase 1 Dose Finding Study

Selected Clinical Pipeline Updates

for June 2021 Non-Muscle Invasive Bladder Cancer (NMIBC) Pancreatic Cancer Triple Negative Breast Cancer (TNBC) M-ceNK COVID-19 HIV Patents

Liquid & Solid Tumor Cell

Therapy Program Off-the-Shelf Natural Killer Cells (NK-92) In-Vivo NK and T Cell Activation (Anktiva) Memory Cytokine Enriched Natural Killer Cells (M-ceNK: Autologous/Allogeneic) Pancreatic Cancer (Ph 2/3) TNBC (Ph 1/2) Lung Cancer (Ph 3) Merkel

Cell Carcinoma (Ph 2) Diffuse Large Cell Lymphoma (Ph 1) GBM (Ph 1) Bladder Cancer (Ph 2/3) Pancreatic Cancer (Ph 2/3) TNBC (Ph 1) Lung Cancer (Ph 3) Indolent Non-Hodgkin Lymphoma (Ph 1) Solid Tumors (Ph 1) Liquid Tumors (Ph 1) Cytokine Cytokine

Fusion Antibody (IgG1) haNK PD-L1 t-haNK CD19 t-haNK HER2 t-haNK EGFR t-haNK t-haNK Anktiva (N-803) M-ceNK

Liquid & Solid Tumor Cell

Therapy Program Off-the-Shelf Natural Killer Cells (NK-92) In-Vivo NK and T Cell Activation (Anktiva) Memory Cytokine Enriched Natural Killer Cells (M-ceNK: Autologous/Allogeneic) Pancreatic Cancer (Ph 2/3) TNBC (Ph 1/2) Lung Cancer (Ph 3) Merkel

Cell Carcinoma (Ph 2) Diffuse Large Cell Lymphoma (Ph 1) GBM (Ph 1) Bladder Cancer (Ph 2/3) Pancreatic Cancer (Ph 2/3) TNBC (Ph 1) Lung Cancer (Ph 3) Indolent Non-Hodgkin Lymphoma (Ph 1) Solid Tumors (Ph 1) Liquid Tumors (Ph 1) Cytokine Cytokine

Fusion Antibody (IgG1) haNK PD-L1 t-haNK CD19 t-haNK HER2 t-haNK EGFR t-haNK t-haNK Anktiva (N-803) M-ceNK